RK-33 is primarily investigated for its potential in cancer therapy, particularly targeting cancers that are resistant to conventional treatments. It works by inhibiting the RNA helicase DDX3, which is often overexpressed in various cancer types. By blocking DDX3, RK-33 disrupts the cancer cells' ability to proliferate and survive, making it a promising candidate for treating aggressive cancers such as breast, lung, and prostate cancer. Additionally, RK-33 is being explored for its role in enhancing the effectiveness of radiation therapy, as it can sensitize cancer cells to radiation, improving treatment outcomes. Its application in combination therapies is also under study, offering hope for more effective and targeted cancer treatments.